Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

Sanofi SNY announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, ...

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Sanofi (NASDAQ:SNY) announced Tuesday that its TIDE-Asthma Phase 2 study for its T-cell-depleting monoclonal antibody ...

Analysts fell to the sidelines weighing in on Sanofi (SNYNF – Research Report) and HealthStream (HSTM – Research Report) with neutral ratings, ...

Sanofi has said “deal” to Chrissy Teigen. The model, cookbook author and “Deal or No Deal” banker has signed on as a ...

The French pharmaceutical major has reportedly slashed the asking price for Lantus from an initial Rs 3,000 crore to Rs 2,000 crore, in a bid to draw more interest.